IRVINE, Calif., Aug. 13 /EMWNews/ -- Endocare, Inc. (Nasdaq: ENDO) announced today that its Board of Directors has unanimously rejected the unsolicited proposal from HealthTronics, Inc. (Nasdaq: HTRN) to purchase all of the outstanding shares of Endocare for $2.28 per share. After careful evaluation, the Board determined that the proposal is inadequate and not in the best interests of Endocare's stockholders.
About Endocare Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).
Investor Contact: Media Contact: For Additional Matt Clawson Len Hall Information: Allen & Caron, Inc. Allen & Caron, Inc. Craig T. Davenport, CEO (949) 474-4300 (949) 474-4300 Michael R. Rodriguez, CFO firstname.lastname@example.org email@example.com Endocare, Inc. http://www.allencaron.com http://www.allencaron.com (949) 450-5400 http://www.endocare.com
Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89